Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $29

Benzinga Newsdesk www.benzinga.com Neutral 63.5%

Neg 0% Neu 63.5% Pos 0%

Canaccord Genuity analyst John Newman initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Buy rating and announces Price Target of $29.